Page 141 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

SUPPLEMENTARY DATA
Supplemental Table 1. Interobserver variability for 89Zr-immuno-PET at D0
89Zr-rituximab
D0
19 (8-31);n=32 3.7 (2.4-5.3)
17 (4-29);n=28 3.4 (2.2-5.3)
18 (9-30);n=32 3.2 (2.0-4.8)
17 (8-24);n=28 3.0 (1.8-4.8)
13 (8-28);n=32 1.6 (1.3-2.3)
12 (8-19);n=28 1.6 (1.3-2.3)
31(17-53);n=32 7.7 (4.4-19.1)
eligible
TLU all 38(23-56);n=32
89Zr-cetuximab
D0
6 (6-19);n=9 2.7 (2.2-5.3)
8 (6-21);n=8 3.2 (2.5-5.4)
5 (4-18);n=9 2.5 (1.8-4.9)
7 (4-21);n=8 3.0 (2.3-5.1)
10 (5-27);n=9 1.8 (1.2-3.1)
17 (5-27);n=8 1.8 (1.7-3.2)
33 (27-55);n=9 3.6 (2.2-9.9)
32 (26-49);n=8 3.2 (2.1-6.1)
38 (33-63);n=9 6 0.01(0.01-0.02)
38 (33-49);n=8 0.01(0.01-0.02)
the first line and VOI metric on the second line
SUVmax all eligible
SUVpeak all eligible
SUVmean all eligible
Volume all (mL)
(%ID)
eligible
0.02(0.01-0.04)
34(20-46);n=28 0.01(0.01-0.04)
26(16-45);n=28 7.7 (3.7-18.0)
Interobserver reproducibility of 89Zr-immuno-PET
Data is presented as interobserver variability (CoV in %) on (median value (interquartile range)).
Supplemental Table 2 ICC calculations for all possible combinations
of 2 observers
SUVmean
O1, O2, O3
O1, O2 O1, O3 O2, O3
89Zr-rituximab 89Zr-cetuximab
D0 D3 D6 D0 D3
89Zr- trastuzumab
D6 D4
0.77 (0.62-0.87)
0.90 0.94 (0.80-0.96) (0.90-0.97)
0.86 0.96 (0.60-0.95) (0.91-0.98)
0.94 0.94 (0.75-0.98) (0.88-0.97)
0.91 0.93 (0.80-0.96) (0.86-0.97)
0.77 (0.41-0.95)
0.79 (0.60-0.90)
0.94 (0.73-0.99)
0.83 (0.65-0.92)
0.61 (-0.05-0.92)
0.69 (0.44-0.85)
0.70 (0.07-0.94)
NA 0.92 0.93 (0.73-0.98) (0.86-0.97)
NA 0.96 0.94 (0.75-0.99) (0.87-0.98)
NA 0.88 0.93 (0.28-0.98) (0.83-0.97)
NA
0.93 0.93 (0.71-0.99) (0.83-0.97)
Data presented as ICC (95% confidence interval).
All ICC calculations were performed on VOI eligible for quantification (n=84).
D0 VOI were delineated on D6 and imported to the D0 scan (data marked in grey).
139